BI-2865, a pan-KRAS inhibitor, reverses the P-glycoprotein induced multidrug resistance in vitro and in vivo
Cell Communication and Signaling · 13.06.2024 · 22 (1)
DOI: 10.1186/s12964-024-01698-4 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cell Communication and Signaling, online erschienen am 13.06.2024. Verfasst von Qihong Yang und 9 weiteren Autor:innen. Beteiligte Einrichtung: People's Hospital of Longhua, Shenzhen, 518109, China. Hauptthemen laut MEDLINE: Drug Resistance, Neoplasm, Drug Resistance, Multiple. Die Arbeit wurde bisher 17-mal zitiert (Crossref) und nennt 46 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China, National Key Research & Development Program of China, Foundation of Guangdong Esophageal Cancer Institute.
Abstract (Originalsprache)
Background
Multidrug resistance (MDR) limits successful cancer chemotherapy. P-glycoprotein (P-gp), BCRP and MRP1 are the key triggers of MDR. Unfortunately, no MDR modulator was approved by FDA to date. Here, we will investigate the effect of BI-2865, a pan-KRAS inhibitor, on reversing MDR induced by P-gp, BCRP and MRP1 in vitro and in vivo, and its reversal mechanisms will be explored.
Methods
The cytotoxicity of BI-2865 and its MDR removal effect in vitro were tested by MTT assays, and the corresponding reversal function in vivo was assessed through the P-gp mediated KBv200 xenografts in mice. BI-2865 induced alterations of drug discharge and reservation in cells were estimated by experiments of Flow cytometry with fluorescent doxorubicin, and the chemo-drug accumulation in xenografts’ tumor were analyzed through LC-MS. Mechanisms of BI-2865 inhibiting P-gp substrate’s efflux were analyzed through the vanadate-sensitive ATPase assay, [ 125 I]-IAAP-photolabeling assay and computer molecular docking. The effects of BI-2865 on P-gp expression and KRAS-downstream signaling were detected via Western blotting, Flow cytometry and/or qRT-PCR. Subcellular localization of P-gp was visualized by Immunofluorescence.
Results
We found BI-2865 notably fortified response of P-gp-driven MDR cancer cells to the administration of chemo-drugs including paclitaxel, vincristine and doxorubicin, while such an effect was not observed in their parental sensitive cells and BCRP or MRP1-driven MDR cells. Importantly, the mice vivo combination study has verified that BI-2865 effectively improved the anti-tumor action of paclitaxel without toxic injury. In mechanism, BI-2865 prompted doxorubicin accumulating in carcinoma cells by directly blocking the efflux function of P-gp, which more specifically, was achieved by BI-2865 competitively binding to the drug-binding sites of P-gp. What’s more, at the effective MDR reversal concentrations, BI-2865 neither varied the expression and location of P-gp nor reduced its downstream AKT or ERK1/2 signaling activity.
Conclusions
This study uncovered a new application of BI-2865 as a MDR modulator, which might be used to effectively, safely and specifically improve chemotherapeutic efficacy in the clinical P-gp mediated MDR refractory cancers.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- People's Hospital of Longhua, Shenzhen, 518109, China.
- State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-sen University Cancer Center, Guangzhou, 510060, P. R. China.
- School of Pharmacy, The Chinese University of Hong Kong, Hong Kong, 999077, China.
- State Key Laboratory of Phytochemistry and Plant Resources in West China, Kunming Institute of Botany, Chinese Academy of Sciences, Kunming, 650201, China.
- People's Hospital of Longhua, Shenzhen, 518109, China. kewangluo@126.com.
- State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-sen University Cancer Center, Guangzhou, 510060, P. R. China. fulw@mail.sysu.edu.cn.
Förderung
- National Natural Science Foundation of China
- National Key Research & Development Program of China
- Foundation of Guangdong Esophageal Cancer Institute
Zitieren
APA
Yang, Q., To, K. K. W., Hu, G., Fu, K., Yang, C., Zhu, S., Pan, C., Wang, F., Luo, K., & Fu, L. (2024). BI-2865, a pan-KRAS inhibitor, reverses the P-glycoprotein induced multidrug resistance in vitro and in vivo. Cell Communication and Signaling, 22(1). https://doi.org/10.1186/s12964-024-01698-4
Vancouver
Yang Q, To KKW, Hu G, Fu K, Yang C, Zhu S, et al. BI-2865, a pan-KRAS inhibitor, reverses the P-glycoprotein induced multidrug resistance in vitro and in vivo. Cell Communication and Signaling. 2024;22(1). doi:10.1186/s12964-024-01698-4
BibTeX
@article{Yang2024,
author = {Yang, Qihong and To, Kenneth Kin Wah and Hu, Guilin and Fu, Kai and Yang, Chuan and Zhu, Shuangli and Pan, Can and Wang, Fang and Luo, Kewang and Fu, Liwu},
title = {BI-2865, a pan-KRAS inhibitor, reverses the P-glycoprotein induced multidrug resistance in vitro and in vivo},
journal = {Cell Communication and Signaling},
year = {2024},
volume = {22},
number = {1},
doi = {10.1186/s12964-024-01698-4}
}
EUVIMED